CFTR and cystic fibrosis: In this context, Declerq et al. (2021) recently reported that the combination of CFTR modulators lumacaftor and ivacaftor (Orkambi®), when applied at concentrations of 3 μM, partially rescued the pro‐inflammatory phenotype of blood outgrowth endothelial cells derived from CF patients with severe disease.